The company confirmed late Thursday that it sold 11.1 million shares, a significant increase from the original plan to offer 9.72 million shares. By setting the price at $18, City Therapeutics landed squarely within its projected range of $17 to $19. The stock is scheduled to begin trading on the Nasdaq Global Market under the ticker symbol CTY.
City Therapeutics Raises $200 Million in Upsized Nasdaq Debut
With an upsized offering priced at $18 per share, Cambridge-based City Therapeutics enters the public market Friday to raise approximately $200 million. The clinical-stage biotechnology firm secured the midpoint of its targeted range, successfully expanding its initial share count to meet investor demand ahead of the Nasdaq listing.
Comments (0)
No comments yet. Be the first!